Express Mail Label No.: EF176736637US

Date of Deposit: March 48, 2002

## Attorney Docket No. CST-138 CIP2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Comb et al.

ASSIGNEE:

CELL SIGNALING TECHNOLOGY, INC.

SERIAL NUMBER:

10/014,485

EXAMINER:

Not yet assigned

FILING DATE:

1.

2.

November

ART UNIT:

1627

PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES USING PEPTIDE LIBRARIES AS ANTIGENS

March 18, 2002

Beverly, Massachusetts

U.S. Patent & Trademark Office Box SEQUENCE, P.O. Box 2327 Arlington, VA 22202

## SUBMISSION OF PAPER COPY AND/OR COMPUTER-READABLE COPY OF SEQUENCE LISTING FOR INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

	NUCLEOTIDE AND/OR AMINO ACID SEQUENCE
$\boxtimes$	This paper is in response to the Patent Office letter dated January 16, 2002.
	A copy of the Patent Office letter is enclosed.
	Note: If these papers are filed before the Patent Office letter is mailed, the adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of the invention, the filing date on the Express Mail Label, the USSN from the return postcard or the attorney's docket number must be added.
	This paper is in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures.
	This paper is being filed simultaneously with a request for filing of a new pater application.
Subm	tted herewith are:
	A Preliminary Amendment directing entry of the Sequence Listing into the specification;
	a paper copy of the Sequence Listing for the above-identified patent application with each sequence assigned a separate identifier; and
$\boxtimes$	a substitute copy of the Sequence Listing in computer-readable form for the above-identified patent application.

APPLICANTS: **U.S.S.N.:** 

Comb et al. 10/014,485

## 3. **Statement:**

I hereby state that: (complete applicable items - A, B and/or C)

- A. The content of the paper and computer-readable copies of the Sequence Listing submitted herewith are the same.
- B. \(\simega\) The content of the computer-readable copy of the Sequence Listing submitted herewith is the same as the Sequence Listing appearing at the end of the originally-filed specification.
- C. This submission includes no new matter.

The substitute computer-readable copy of the Sequence Listing submitted herewith corrects the format errors in the originally-filed computer-readable copy. Specifically, the <223> responses for SEQ ID NOs: 88, 96, 101, 105, 109, and 111 have been revised to comply with the 4 line limit of 37 C.F.R. §1.823(b). For the Sequence examiner's convenience, paper copies of these revised responses are enclosed herewith.

Applicants believe that no fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-1774, Ref. No. CST-138 CIP2.

Respectfully submitted,

James Oregory Cullem, Reg. No. 43,569

Intellectual Property Counsel

CELL SIGNALING TECHNOLOGY, INC.

166B Cummings Center Beverely, MA 01915 (978) 867-2311

Dated: March 18, 2002